nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—Ifosfamide—testicular cancer	0.175	0.229	CbGbCtD
Nevirapine—CYP2B6—Ifosfamide—testicular cancer	0.114	0.149	CbGbCtD
Nevirapine—CYP3A5—Ifosfamide—testicular cancer	0.0896	0.117	CbGbCtD
Nevirapine—CYP2C9—Ifosfamide—testicular cancer	0.0601	0.0787	CbGbCtD
Nevirapine—CYP2B6—Cisplatin—testicular cancer	0.0553	0.0725	CbGbCtD
Nevirapine—CYP3A5—Etoposide—testicular cancer	0.0428	0.0561	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—testicular cancer	0.0371	0.0486	CbGbCtD
Nevirapine—CYP3A4—Ifosfamide—testicular cancer	0.0349	0.0458	CbGbCtD
Nevirapine—CYP1A2—Etoposide—testicular cancer	0.0319	0.0418	CbGbCtD
Nevirapine—CYP2C9—Cisplatin—testicular cancer	0.0292	0.0383	CbGbCtD
Nevirapine—CYP2D6—Vinblastine—testicular cancer	0.0292	0.0382	CbGbCtD
Nevirapine—CYP3A4—Vinblastine—testicular cancer	0.0185	0.0243	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—testicular cancer	0.0179	0.0235	CbGbCtD
Nevirapine—CYP3A4—Etoposide—testicular cancer	0.0167	0.0219	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—testicular cancer	0.0114	0.0149	CbGbCtD
Nevirapine—Feeling abnormal—Dactinomycin—testicular cancer	0.000393	0.00166	CcSEcCtD
Nevirapine—Nausea—Chlorambucil—testicular cancer	0.000392	0.00166	CcSEcCtD
Nevirapine—Paraesthesia—Ifosfamide—testicular cancer	0.000392	0.00166	CcSEcCtD
Nevirapine—Ill-defined disorder—Etoposide—testicular cancer	0.000392	0.00166	CcSEcCtD
Nevirapine—Anaemia—Etoposide—testicular cancer	0.000391	0.00165	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00039	0.00165	CcSEcCtD
Nevirapine—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00039	0.00165	CcSEcCtD
Nevirapine—Somnolence—Ifosfamide—testicular cancer	0.000388	0.00164	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—testicular cancer	0.000388	0.00164	CcSEcCtD
Nevirapine—Discomfort—Cisplatin—testicular cancer	0.000388	0.00164	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Doxorubicin—testicular cancer	0.000386	0.00163	CcSEcCtD
Nevirapine—Vomiting—Vinblastine—testicular cancer	0.000385	0.00162	CcSEcCtD
Nevirapine—Malaise—Etoposide—testicular cancer	0.000381	0.00161	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—testicular cancer	0.000381	0.00161	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—testicular cancer	0.00038	0.0016	CcSEcCtD
Nevirapine—Decreased appetite—Ifosfamide—testicular cancer	0.00038	0.0016	CcSEcCtD
Nevirapine—Headache—Vinblastine—testicular cancer	0.000379	0.0016	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000379	0.0016	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000377	0.00159	CcSEcCtD
Nevirapine—Abdominal pain—Dactinomycin—testicular cancer	0.000377	0.00159	CcSEcCtD
Nevirapine—Body temperature increased—Dactinomycin—testicular cancer	0.000377	0.00159	CcSEcCtD
Nevirapine—Fatigue—Ifosfamide—testicular cancer	0.000377	0.00159	CcSEcCtD
Nevirapine—Oedema—Cisplatin—testicular cancer	0.000377	0.00159	CcSEcCtD
Nevirapine—Anaphylactic shock—Cisplatin—testicular cancer	0.000377	0.00159	CcSEcCtD
Nevirapine—Hypersensitivity—Bleomycin—testicular cancer	0.000377	0.00159	CcSEcCtD
Nevirapine—Pain—Ifosfamide—testicular cancer	0.000374	0.00158	CcSEcCtD
Nevirapine—Nervous system disorder—Cisplatin—testicular cancer	0.000369	0.00156	CcSEcCtD
Nevirapine—Thrombocytopenia—Cisplatin—testicular cancer	0.000369	0.00156	CcSEcCtD
Nevirapine—Asthenia—Bleomycin—testicular cancer	0.000367	0.00155	CcSEcCtD
Nevirapine—Skin disorder—Cisplatin—testicular cancer	0.000366	0.00154	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—testicular cancer	0.000363	0.00153	CcSEcCtD
Nevirapine—Pruritus—Bleomycin—testicular cancer	0.000362	0.00153	CcSEcCtD
Nevirapine—Feeling abnormal—Ifosfamide—testicular cancer	0.00036	0.00152	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—testicular cancer	0.00036	0.00152	CcSEcCtD
Nevirapine—Nausea—Vinblastine—testicular cancer	0.00036	0.00152	CcSEcCtD
Nevirapine—Anorexia—Cisplatin—testicular cancer	0.000359	0.00152	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000358	0.00151	CcSEcCtD
Nevirapine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000357	0.00151	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—testicular cancer	0.000356	0.0015	CcSEcCtD
Nevirapine—Discomfort—Etoposide—testicular cancer	0.000356	0.0015	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000354	0.0015	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000354	0.0015	CcSEcCtD
Nevirapine—Face oedema—Doxorubicin—testicular cancer	0.000352	0.00148	CcSEcCtD
Nevirapine—Hypersensitivity—Dactinomycin—testicular cancer	0.000351	0.00148	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000347	0.00147	CcSEcCtD
Nevirapine—Urticaria—Ifosfamide—testicular cancer	0.000347	0.00147	CcSEcCtD
Nevirapine—Abdominal pain—Ifosfamide—testicular cancer	0.000345	0.00146	CcSEcCtD
Nevirapine—Body temperature increased—Ifosfamide—testicular cancer	0.000345	0.00146	CcSEcCtD
Nevirapine—Anaphylactic shock—Etoposide—testicular cancer	0.000345	0.00146	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000343	0.00145	CcSEcCtD
Nevirapine—Asthenia—Dactinomycin—testicular cancer	0.000342	0.00144	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—testicular cancer	0.00034	0.00143	CcSEcCtD
Nevirapine—Paraesthesia—Cisplatin—testicular cancer	0.000338	0.00143	CcSEcCtD
Nevirapine—Thrombocytopenia—Etoposide—testicular cancer	0.000338	0.00143	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—testicular cancer	0.000337	0.00142	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—testicular cancer	0.000336	0.00142	CcSEcCtD
Nevirapine—Skin disorder—Etoposide—testicular cancer	0.000335	0.00142	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—testicular cancer	0.000334	0.00141	CcSEcCtD
Nevirapine—Anorexia—Etoposide—testicular cancer	0.000329	0.00139	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000328	0.00138	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000328	0.00138	CcSEcCtD
Nevirapine—Decreased appetite—Cisplatin—testicular cancer	0.000327	0.00138	CcSEcCtD
Nevirapine—Diarrhoea—Dactinomycin—testicular cancer	0.000326	0.00138	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000325	0.00137	CcSEcCtD
Nevirapine—Vomiting—Bleomycin—testicular cancer	0.000325	0.00137	CcSEcCtD
Nevirapine—Rash—Bleomycin—testicular cancer	0.000322	0.00136	CcSEcCtD
Nevirapine—Pain—Cisplatin—testicular cancer	0.000322	0.00136	CcSEcCtD
Nevirapine—Dermatitis—Bleomycin—testicular cancer	0.000322	0.00136	CcSEcCtD
Nevirapine—Hypersensitivity—Ifosfamide—testicular cancer	0.000322	0.00136	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000321	0.00136	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000321	0.00136	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—testicular cancer	0.000319	0.00134	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—testicular cancer	0.000318	0.00134	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—testicular cancer	0.000315	0.00133	CcSEcCtD
Nevirapine—Asthenia—Ifosfamide—testicular cancer	0.000314	0.00132	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—testicular cancer	0.000312	0.00132	CcSEcCtD
Nevirapine—Feeling abnormal—Cisplatin—testicular cancer	0.00031	0.00131	CcSEcCtD
Nevirapine—Paraesthesia—Etoposide—testicular cancer	0.00031	0.00131	CcSEcCtD
Nevirapine—Pruritus—Ifosfamide—testicular cancer	0.000309	0.00131	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—testicular cancer	0.000309	0.0013	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—testicular cancer	0.000307	0.0013	CcSEcCtD
Nevirapine—Somnolence—Etoposide—testicular cancer	0.000307	0.0013	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—testicular cancer	0.000307	0.00129	CcSEcCtD
Nevirapine—Nausea—Bleomycin—testicular cancer	0.000304	0.00128	CcSEcCtD
Nevirapine—Vomiting—Dactinomycin—testicular cancer	0.000303	0.00128	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—testicular cancer	0.000302	0.00128	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000301	0.00127	CcSEcCtD
Nevirapine—Rash—Dactinomycin—testicular cancer	0.000301	0.00127	CcSEcCtD
Nevirapine—Decreased appetite—Etoposide—testicular cancer	0.0003	0.00127	CcSEcCtD
Nevirapine—Diarrhoea—Ifosfamide—testicular cancer	0.000299	0.00126	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—testicular cancer	0.000298	0.00126	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000298	0.00126	CcSEcCtD
Nevirapine—Body temperature increased—Cisplatin—testicular cancer	0.000298	0.00126	CcSEcCtD
Nevirapine—Fatigue—Etoposide—testicular cancer	0.000298	0.00126	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—testicular cancer	0.000297	0.00126	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—testicular cancer	0.000296	0.00125	CcSEcCtD
Nevirapine—Pain—Etoposide—testicular cancer	0.000295	0.00125	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—testicular cancer	0.000295	0.00124	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—testicular cancer	0.000294	0.00124	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—testicular cancer	0.000291	0.00123	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—testicular cancer	0.000287	0.00121	CcSEcCtD
Nevirapine—Feeling abnormal—Etoposide—testicular cancer	0.000284	0.0012	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—testicular cancer	0.000284	0.0012	CcSEcCtD
Nevirapine—Nausea—Dactinomycin—testicular cancer	0.000283	0.0012	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—testicular cancer	0.000283	0.00119	CcSEcCtD
Nevirapine—Gastrointestinal pain—Etoposide—testicular cancer	0.000282	0.00119	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000278	0.00117	CcSEcCtD
Nevirapine—Vomiting—Ifosfamide—testicular cancer	0.000278	0.00117	CcSEcCtD
Nevirapine—Hypersensitivity—Cisplatin—testicular cancer	0.000278	0.00117	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—testicular cancer	0.000276	0.00116	CcSEcCtD
Nevirapine—Rash—Ifosfamide—testicular cancer	0.000276	0.00116	CcSEcCtD
Nevirapine—Dermatitis—Ifosfamide—testicular cancer	0.000275	0.00116	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—testicular cancer	0.000275	0.00116	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000275	0.00116	CcSEcCtD
Nevirapine—Urticaria—Etoposide—testicular cancer	0.000274	0.00116	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—testicular cancer	0.000274	0.00115	CcSEcCtD
Nevirapine—Abdominal pain—Etoposide—testicular cancer	0.000273	0.00115	CcSEcCtD
Nevirapine—Body temperature increased—Etoposide—testicular cancer	0.000273	0.00115	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—testicular cancer	0.000273	0.00115	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—testicular cancer	0.000272	0.00115	CcSEcCtD
Nevirapine—Asthenia—Cisplatin—testicular cancer	0.00027	0.00114	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—testicular cancer	0.000268	0.00113	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000265	0.00112	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—testicular cancer	0.000263	0.00111	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—testicular cancer	0.000262	0.00111	CcSEcCtD
Nevirapine—Nausea—Ifosfamide—testicular cancer	0.00026	0.0011	CcSEcCtD
Nevirapine—Diarrhoea—Cisplatin—testicular cancer	0.000258	0.00109	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—testicular cancer	0.000257	0.00109	CcSEcCtD
Nevirapine—Hypersensitivity—Etoposide—testicular cancer	0.000254	0.00107	CcSEcCtD
Nevirapine—Erythema—Methotrexate—testicular cancer	0.000253	0.00107	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—testicular cancer	0.000252	0.00106	CcSEcCtD
Nevirapine—Asthenia—Etoposide—testicular cancer	0.000248	0.00105	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000248	0.00105	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—testicular cancer	0.000246	0.00104	CcSEcCtD
Nevirapine—Pruritus—Etoposide—testicular cancer	0.000244	0.00103	CcSEcCtD
Nevirapine—Vomiting—Cisplatin—testicular cancer	0.00024	0.00101	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—testicular cancer	0.000238	0.00101	CcSEcCtD
Nevirapine—Rash—Cisplatin—testicular cancer	0.000238	0.001	CcSEcCtD
Nevirapine—Dermatitis—Cisplatin—testicular cancer	0.000237	0.001	CcSEcCtD
Nevirapine—Erythema—Epirubicin—testicular cancer	0.000237	0.001	CcSEcCtD
Nevirapine—Diarrhoea—Etoposide—testicular cancer	0.000236	0.000997	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—testicular cancer	0.000235	0.000992	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—testicular cancer	0.000234	0.000988	CcSEcCtD
Nevirapine—Malaise—Methotrexate—testicular cancer	0.000228	0.000964	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—testicular cancer	0.000228	0.000961	CcSEcCtD
Nevirapine—Nausea—Cisplatin—testicular cancer	0.000224	0.000945	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—testicular cancer	0.00022	0.000928	CcSEcCtD
Nevirapine—Vomiting—Etoposide—testicular cancer	0.000219	0.000926	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—testicular cancer	0.000219	0.000926	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—testicular cancer	0.000219	0.000925	CcSEcCtD
Nevirapine—Rash—Etoposide—testicular cancer	0.000218	0.000919	CcSEcCtD
Nevirapine—Dermatitis—Etoposide—testicular cancer	0.000217	0.000918	CcSEcCtD
Nevirapine—Headache—Etoposide—testicular cancer	0.000216	0.000913	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—testicular cancer	0.000216	0.00091	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—testicular cancer	0.000216	0.00091	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000214	0.000904	CcSEcCtD
Nevirapine—Malaise—Epirubicin—testicular cancer	0.000214	0.000902	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—testicular cancer	0.000213	0.000899	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—testicular cancer	0.000207	0.000873	CcSEcCtD
Nevirapine—Nausea—Etoposide—testicular cancer	0.000205	0.000865	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000203	0.000859	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—testicular cancer	0.000203	0.000856	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—testicular cancer	0.000203	0.000856	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—testicular cancer	0.000202	0.000854	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—testicular cancer	0.000202	0.000852	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—testicular cancer	0.000202	0.000852	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—testicular cancer	0.000201	0.000848	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.0002	0.000846	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—testicular cancer	0.000199	0.000842	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—testicular cancer	0.000198	0.000835	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—testicular cancer	0.000197	0.000832	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—testicular cancer	0.000193	0.000817	CcSEcCtD
Nevirapine—Oedema—Epirubicin—testicular cancer	0.000193	0.000817	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—testicular cancer	0.00019	0.000801	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—testicular cancer	0.000189	0.0008	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000188	0.000795	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—testicular cancer	0.000188	0.000793	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—testicular cancer	0.000187	0.000788	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—testicular cancer	0.000187	0.000788	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—testicular cancer	0.000186	0.000784	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000185	0.000783	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—testicular cancer	0.000184	0.000779	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—testicular cancer	0.000184	0.000778	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—testicular cancer	0.000184	0.000776	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—testicular cancer	0.00018	0.000759	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000179	0.000756	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—testicular cancer	0.000179	0.000756	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000178	0.000753	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—testicular cancer	0.000178	0.000752	CcSEcCtD
Nevirapine—Pain—Methotrexate—testicular cancer	0.000177	0.000746	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000176	0.000744	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—testicular cancer	0.000176	0.000741	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000175	0.00074	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—testicular cancer	0.000174	0.000734	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—testicular cancer	0.000174	0.000733	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—testicular cancer	0.000172	0.000726	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—testicular cancer	0.000171	0.00072	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—testicular cancer	0.00017	0.000719	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000169	0.000714	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—testicular cancer	0.000168	0.00071	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000167	0.000705	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—testicular cancer	0.000167	0.000704	CcSEcCtD
Nevirapine—Pain—Epirubicin—testicular cancer	0.000165	0.000698	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—testicular cancer	0.000164	0.000693	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—testicular cancer	0.000163	0.00069	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—testicular cancer	0.000163	0.00069	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000163	0.000688	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—testicular cancer	0.000161	0.000679	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—testicular cancer	0.000159	0.000673	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—testicular cancer	0.000159	0.000672	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000158	0.000668	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—testicular cancer	0.000156	0.000657	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000155	0.000652	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—testicular cancer	0.000154	0.000651	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—testicular cancer	0.000154	0.000649	CcSEcCtD
Nevirapine—Pain—Doxorubicin—testicular cancer	0.000153	0.000646	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—testicular cancer	0.000153	0.000646	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—testicular cancer	0.000153	0.000646	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—testicular cancer	0.000152	0.000643	CcSEcCtD
Nevirapine—Asthenia—Methotrexate—testicular cancer	0.000148	0.000626	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—testicular cancer	0.000148	0.000623	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000146	0.000618	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—testicular cancer	0.000146	0.000617	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—testicular cancer	0.000143	0.000602	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—testicular cancer	0.000142	0.0006	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—testicular cancer	0.000142	0.000597	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—testicular cancer	0.000142	0.000597	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—testicular cancer	0.000141	0.000597	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—testicular cancer	0.000139	0.000586	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—testicular cancer	0.000137	0.000578	CcSEcCtD
Nevirapine—Diarrhoea—Epirubicin—testicular cancer	0.000132	0.000559	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—testicular cancer	0.000132	0.000557	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—testicular cancer	0.000131	0.000555	CcSEcCtD
Nevirapine—Rash—Methotrexate—testicular cancer	0.00013	0.00055	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—testicular cancer	0.00013	0.00055	CcSEcCtD
Nevirapine—Headache—Methotrexate—testicular cancer	0.00013	0.000547	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—testicular cancer	0.000128	0.000542	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—testicular cancer	0.000127	0.000535	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—testicular cancer	0.000123	0.000519	CcSEcCtD
Nevirapine—Nausea—Methotrexate—testicular cancer	0.000123	0.000518	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—testicular cancer	0.000122	0.000517	CcSEcCtD
Nevirapine—Rash—Epirubicin—testicular cancer	0.000122	0.000515	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—testicular cancer	0.000122	0.000514	CcSEcCtD
Nevirapine—Headache—Epirubicin—testicular cancer	0.000121	0.000512	CcSEcCtD
Nevirapine—Nausea—Epirubicin—testicular cancer	0.000115	0.000485	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—testicular cancer	0.000114	0.00048	CcSEcCtD
Nevirapine—Rash—Doxorubicin—testicular cancer	0.000113	0.000476	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—testicular cancer	0.000113	0.000476	CcSEcCtD
Nevirapine—Headache—Doxorubicin—testicular cancer	0.000112	0.000473	CcSEcCtD
Nevirapine—Nausea—Doxorubicin—testicular cancer	0.000106	0.000449	CcSEcCtD
